The U.S. Food and Drug Administration (FDA) has accepted to review two new Merck applications requesting the approval of Keytruda (pembrolizumab) for the treatment of patients with different forms of triple-negative breast cancer (TNBC). One of the two supplemental biologics license applications (sBLAs) was granted priority review, which speeds FDA action, with a Prescription Drug User Fee Act ( That means the U.S. regulatory agency will make a decision by that date on whether to approve…
You must be logged in to read/download the full post.
The post FDA Will Review Two New Applications Seeking Keytruda Approval for TNBC appeared first on BioNewsFeeds.